The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Apoptosis in Parkinson's disease: Signals for neuronal degradation
Abstract
Controversy has surrounded a role for apoptosis in the loss of neurons in Parkinson's disease (PD). Although a variety of evidence has supported an apoptotic contribution to PD neuronal loss particularly in the nigra, two factors have weighed against general acceptance: (1) limitations in the use of in situ 3' end labeling techniques to demonstrate nuclear DNA cleavage; and (2) the insistence that a specific set of nuclear morphological features be present before apoptotic death could be declared. We first review the molecular events that underlie apoptotic nuclear degradation and the literature regarding the unreliability of 3' DNA end labeling as a marker of apoptotic nuclear degradation. Recent findings regarding the multiple caspase-dependent or caspase-independent signaling pathways that mediate apoptotic nuclear degradation and determine the morphological features of apoptotic nuclear degradation are presented. The evidence shows that a single nuclear morphology is not sufficient to identify apoptosis and that a cytochrome c, pro-caspase 9, and caspase 3 pathways is operative in PD nigral apoptosis. BAX-dependent increases in mitochondrial membrane permeability are responsible for the release of mitochondrial factors that signal for apoptotic degradation, and increased BAX levels have been found in a subset of PD nigral neurons. Studies using immunocytochemistry in PD postmortem nigra have begun to define the premitochondrial apoptosis signaling pathways in the disease. Two, possibly interdependent, pathways have been uncovered: (1) a p53-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-BAX pathway; and (2) FAS receptor-FADD-caspase 8-BAX pathway. Based on the above, it seems unlikely that apoptosis does not contribute to PD neuronal loss, and the definition of the premitochondrial signaling pathways may allow for the development and testing of an apoptosis-based PD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Molecular characterization of mitochondrial apoptosis-inducing factor
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et al. (1999) · Nature · doi:10.1038/17135 · Cited by 4,060
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
TNF-R1 Signaling: A Beautiful Pathway
Chen, G., & Goeddel, D. V. (2002) · Science · doi:10.1126/science.1071924 · Cited by 1,927
Endonuclease G is an apoptotic DNase when released from mitochondria
Li, L. Y., Luo, X., & Wang, X. (2001) · Nature · doi:10.1038/35083620 · Cited by 1,787 · cited 1×
“Finally, a mitochondrial DNase, endonuclease G that normally acts on mitochondrial DNA can be released from mitochondria.(31,32) Nuclear DNA fragmentation caused by endonuclease G is independent of either caspase or CAD activity as shown in Figure 2.”
BackgroundFour deaths and a funeral: from caspases to alternative mechanisms
Leist, M., & Jäättelä, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085008 · Cited by 1,587
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Self-citationMétézeau, P. (1998) · Research in Microbiology · doi:10.1016/s0923-2508(98)80442-7 · Cited by 1,243
Bid Induces the Oligomerization and Insertion of Bax into the Outer Mitochondrial Membrane
Eskes, R., Desagher, S., Antonsson, B., & Martinou, J.-C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.929-935.2000 · Cited by 1,189
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Prigent, A., Ruberg, M., Hirsch, É. C., & Agid, Y. (1997) · PubMed · Cited by 1,188
Cited by
Cell death: a review of the major forms of apoptosis, necrosis and autophagy
D’Arcy, M. S. (2019) · Cell Biology International · doi:10.1002/cbin.11137 · Cited by 2,307
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Wharram, B. L., Goyal, M., Wiggins, J. E., Sanden, S. K., Hussain, S., Filipiak, W. E., Saunders, T. L., Dysko, R. C., Kohno, K., Holzman, L. B., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010055 · Cited by 737
Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences
Tezel, G. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.07.003 · Cited by 723
High-Resolution Whole-Genome Association Study of Parkinson Disease
Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., Pant, P. V. K., Frazer, K. A., Cox, D. R., & Ballinger, D. G. (2005) · The American Journal of Human Genetics · doi:10.1086/496902 · Cited by 508
Nutraceutical Antioxidants as Novel Neuroprotective Agents
Kelsey, N. A., Wilkins, H. M., & Linseman, D. A. (2010) · Molecules · doi:10.3390/molecules15117792 · Cited by 480
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Scholz, J., Broom, D. C., Youn, D.-H., Mills, C. D., Kohno, T., Suter, M. R., Moore, K. A., Decosterd, I., Coggeshall, R. E., & Woolf, C. J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1526-05.2005 · Cited by 436
Simunovic, F., Yi, M., Wang, Y., Macey, L., Brown, L. T., Krichevsky, A. M., Andersen, S. L., Stephens, R. M., Benes, F. M., & Sonntag, K. C. (2009) · Brain · doi:10.1093/brain/awn323 · Cited by 354
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 288
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“Whether PCD actually occurs within the human PD brain remains controversial, and this possibility has been neither confirmed by numerous studies nor definitely excluded (Jellinger 2006; Tatton et al. 2003).”
ResultNandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., McKenzie, J., McCormick, S., Samii, A., Troiano, A., et al. (2009) · Brain · doi:10.1093/brain/awp209 · Cited by 259
Abdelkader, N. F., Safar, M. M., & Salem, H. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9043-8 · Cited by 127
Wang, J., Liu, H., Zhang, X., Li, X., Geng, L., Zhang, H., & Zhang, Q. (2017) · Marine Drugs · doi:10.3390/md15040110 · Cited by 41
Ramiro-Cortés, Y., & Morán, J. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.05.015 · Cited by 33
Metadata
- Authors
- Tatton, W. G., Chalmers-Redman, R., Brown, D., & Tatton, N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2003
- Volume
- 53
- Issue
- S3
- Pages
- S61-S72
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2006059185
- Cited by
- 397
- References
- 94
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.